BofA lowered the firm’s price target on LianBio (LIAN) to $5 from $6 given net changes to cash and termination of mavacemten rights in Asia, while keeping a Buy rating on the shares. The firm pointed out in a research note on Friday that Lianbio has announced termination of its license agreement to sell Mavacemten in Asia with Bristol (BMY) in exchange for $350M and relief of $120M in milestone payment obligations. Following the termination, management announced that they were entering a strategic review to “realize the value of the company’s platform and product candidates.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LIAN:
- LianBio reports Q3 EPS (22c), consensus (30c)
- LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- LianBio to discuss Phase 3 LIBRA results with China NMPA
- LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023
- LianBio enters pact with Bristol Myers for Mavacamten in China, Asian markets